Document:

Exhibit 10.19

 

AMENDED AND RESTATED CONSULTING AGREEMENT

 

This
Amended and Restated Consulting Agreement (the “Agreement”) is entered into on October 25, 2016 (the “Execution
Date”), and made effective as of July 17, 2013 (the “Effective Date”), by and between LYL Holdings
Inc., a corporation and successor in interest to this Agreement (the “Consultant”), and Opiant Pharmaceuticals,
Inc., a Nevada corporation (the “Company”).

 

WHEREAS, on the Effective Date, the Company
entered into that certain consulting agreement (the “Initial Consulting Agreement”), as amended by a subsequent
letter agreement dated October 15, 2014, by and between the Company and two third party consultants (the “Letter Agreement”
and, together with the Initial Consulting Agreement, the “Initial Agreement”), whereby the third party consultants,
using their expertise in the biopharmaceutical space, provided certain consulting and advisory services to the Company during the
period commencing on the Effective Date through the three (3) year anniversary of the Effective Date (the “Services”);

 

WHEREAS, the Company has developed a
treatment to reverse opioid overdoses (known as NARCAN® (naloxone hydrochloride) Nasal Spray (the “Product”);

 

WHEREAS, pursuant to the Initial Agreement,
the Company, in exchange for the Services provided by the third party consultants, assigned the third party consultants the right
to receive a certain amount of the financial return produced by the Product; and

 

WHEREAS, the third party consultants
have since assigned their rights and obligations under the Initial Agreement to the Consultant and the Consultant and the Company
now desire to amend and restate the Initial Agreement to (i) reflect the occurrence of events since the Effective Date, (ii) incorporate
the terms of the Letter Agreement and (iii) add the Consultant, and remove the third party consultants, as a party to this Agreement.

 

NOW, THEREFORE,
with reference to the foregoing facts, the Company and the Consultant agree as follows:

 

		1.	Interest Assignment.

 

1.1         In exchange for
the Services provided by the third party consultants, the Consultant shall receive the right to receive, pro rata, five percent
(5%) of the Net Profit generated from the Product in perpetuity from the Effective Date (the “Interest”). “Net
Profit” shall be defined as any pre-tax revenue received by the Company that was derived from the sale of the Product
less any and all expenses incurred by and payments made by the Company in connection with the Product, including but not limited
to an allocation of Company overhead based on the proportionate time, expenses and resources devoted by the Company to Product-related
activities, which allocation shall be determined in good faith by the Company.

 

		2.	Net Profit Audits, Updates, Distributions and Other Transactions.

 

2.1         The Company shall
provide the Consultant with an annual audit of Net Profit (the “Audit”), which Audit shall be completed after
the end of each calendar year.  Notwithstanding the foregoing, this Paragraph 2.1 shall not be applicable until the Product
generates Net Profit.

 

2.2         After the end of
each quarter of the calendar year, the Company shall provide the Consultant with a written or electronic update with respect to
the status of the Product. If the Product generates Net Profit, then the Company shall also provide the Consultant with a written
or electronic statement of the estimated Net Profit represented by the Interest.

 

    	 	 	 

     

    

 

2.3         After the end of
each of the first three quarters of the calendar year, the Company shall distribute to the Consultant eighty percent (80%) of such
calendar quarter’s Net Profit represented by the Interest, which amount shall be estimated in good faith by the Company.
Upon the completion of the Audit for such calendar year, the Company shall distribute to the Consultant the Net Profit represented
by the Interest for the fourth quarter of the calendar year. In the event that the Audit for such calendar year determines the
Net Profit represented by the Interest for the first three quarters of the calendar year (the “Audited NP”)
to be greater than the estimated Net Profit represented by the Interest actually paid to the Consultant for the first three calendar
quarters (the “Estimated NP”), then the Company shall distribute to the Consultant the difference between the
Audited NP and the Estimated NP. In the event that the Audit for such calendar year determines the Audited NP to be less than the
Estimated NP, then the Company shall deduct the difference between the Estimated NP and the Audited NP from the distribution for
the fourth quarter of such calendar year and, if required, each following distribution until such amount is fully deducted.

 

2.4         In the event that
the Product is sold by the Company, then the Consultant shall receive five percent (5%) of the net proceeds of such sale, pro rata,
and in the form of such net proceeds, after the deduction of all expenses and costs related to such sale. In the event that the
Company is sold, then the Company shall engage an independent financial or accounting firm to determine the fair value of the Company
which is directly attributable to the Product and the Consultant shall receive five percent (5%) of such amount after the deduction
of all expenses and costs related to such sale. All other material transactions involving the Product not addressed herein shall
be addressed in good faith by the Company and the Consultant.

 

		3.	Representations and Warranties of the Company.

 

The Company represents
and warrants to the Consultant that:

 

3.1         The Company is a public
company duly organized, validly existing and in good standing under the laws of Nevada and has all requisite power and authority
to own, lease and operate its properties and assets and to carry on its business as now being conducted and as proposed to be conducted.

 

3.2         This Agreement has
been duly executed and delivered by the Company and constitutes a valid and legally binding obligation of the Company enforceable
against the Company in accordance with its terms, subject to the effect of bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance and other similar laws relating to or affecting creditors' rights generally, or the availability of
equitable remedies.

  

		4.	Acknowledgements, Agreements and Covenant of Consultant.

 

The Consultant acknowledges,
agrees with, and covenants to, the Company as follows:

 

4.1         Opportunities for
Additional Information. The Consultant acknowledges that the Consultant has not received any information from the Company regarding
this investment. The Consultant has the opportunity to ask questions of and receive answers from, or obtain additional information
from, the executive officers of the Company concerning the financial and other affairs of the Company. The Consultant has not asked
such questions from the Company and is making its own decision without input and the Consultant desires to invest in the Company.

 

    	 	 2	 

     

    

 

4.2         No Guarantee of
Success. The Consultant acknowledges that this is a speculative investment involving a high degree of risk and that there is
no guarantee of success or that the Consultant will realize any gain from this investment, and the Consultant could lose the total
amount of its investment.

 

4.3         Adapt Agreement.
All amounts that the Consultant may be entitled to receive in respect of proceeds received by the Company from the Company’s
License Agreement, dated December 15, 2014, by and between the Company and Adapt Pharma Operations Limited, a wholly owned subsidiary
of Adapt Pharma Limited (“Adapt”), an Ireland-based pharmaceutical company (the “Adapt Agreement”),
or received by the Company from any transaction contemplated by the Adapt Agreement, shall be the responsibility and obligation
solely of the Company or its successor. The Consultant agrees and covenants, for the benefit of the Company and Adapt, Adapt’s
successors, assigns and sublicensees and each of their respective shareholders, directors, officers and employees (the “Adapt
Parties”), that it shall under no circumstances seek payment or other compensation for any such amount directly from
any Adapt Party or assert any claim against any Adapt Party in relation to the Adapt Agreement or any transactions contemplated
thereby. 

 

		6.	Miscellaneous.

 

6.1         Notices.  All
notices, requests, demands and other communications (collectively, “Notices”) given pursuant to this Agreement
shall be electronic or in writing, and shall be delivered by email or by personal service, courier, facsimile transmission or by
United States first class, registered or certified mail, postage prepaid, addressed to the party at the address set forth on the
signature page to this Agreement.  Any Notice, other than a Notice sent by registered or certified mail, shall be effective
when received; a Notice sent by registered or certified mail, postage prepaid return receipt requested, shall be effective on the
earlier of when received or the fifth day following deposit in the United States mails.  Any party may from time to time
change its address for further Notices hereunder by giving notice to the other party in the manner prescribed in this Paragraph.
Notwithstanding the foregoing, the Company may send the information set forth in Paragraphs 2.1 and 2.2 via email.

 

6.2         Entire Agreement.  This
Agreement contains the sole and entire agreement and understanding of the parties with respect to the entire subject matter of
this Agreement, and any and all prior discussions, negotiations, commitments and understandings, whether oral or otherwise, related
to the subject matter of this Agreement are hereby merged herein.

 

6.3         Successors.  This
Agreement shall be binding upon and inure to the benefit of the parties to this Agreement and their respective successors, heirs
and personal representatives.

 

6.4         Waiver and Amendment.  No
provision of this Agreement may be waived unless in writing signed by all the parties to this Agreement, and waiver of any one
provision of this Agreement shall not be deemed to be a waiver of any other provision.  This Agreement may be amended
only by a written agreement executed by all of the parties to this Agreement.

 

6.4         Governing Law.  This
Agreement shall be construed in accordance with the laws of the State of Nevada without giving effect to the principles of conflicts
of law thereof.

 

6.5         Third Party Beneficiaries.
The Company and the Consultant agree that the Adapt Parties are express third party beneficiaries solely with respect to
the Consultant’s covenant contained in Paragraph 4.3 of this Agreement and the Adapt Parties may enforce such provision
hereof, and that the foregoing covenant is a material inducement to Adapt continuing to be a party to the Adapt Agreement.

 

    	 	 3	 

     

    

 

6.5         Captions.  The
various captions of this Agreement are for reference only and shall not be considered or referred to in resolving questions of
interpretation of this Agreement.

 

6.6         Execution.  This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood
that both parties need not sign the same counterpart.  In the event that any signature is delivered by facsimile transmission
or by email delivery of a “pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “pdf”
signature page were an original thereof.

 

[Signature Page Follows]

 

    	 	 4	 

     

    

 

IN WITNESS WHEREOF, the
Company and the Consultant have duly executed this Agreement as of the Execution Date.

 

	OPIANT PHARMACEUTICALS, INC.	 
	 	 	 
	By:	/s/ Dr. Roger Crystal	 
	 	 	 
	Name:	Dr. Roger Crystal	 
	 	 	 
	Its:	Chief Executive Officer	 

 

	Address:	401 Wilshire Blvd., 12th Floor,	 
	 	Santa Monica, CA 90401	 
	 	 
	Attn: Dr. Roger Crystal	 
	 	 
	Tel.: (424) 252-4756	 
	 	 
	Email: rcrystal@opiant.com	 
	 	 
	LYL HOLDINGS INC.	 

 

	By:	/s/ Bradley Miles	 
	 	 	 
	Name:	Bradley Miles

	 
	 	 
	Its:	President

	 
	 	 
	Address:	 
	 	 
	Attn:	 
	 	 
	Tel.:	 
	 	 
	Email:Exhibit 10.20

 

INVESTMENT AGREEMENT

 

This Investment Agreement
(this “Agreement”) is made and entered as of May 15, 2014 (the “Effective Date”) by and between
Lightlake Therapeutics Inc., a Nevada corporation (the “Company”), and Ernst Welmers (the “Investor”).

 

WHEREAS, the Company is developing
a naloxone hydrochloride nasal spray for the emergency reversal of heroin or opioid overdose, which naloxone hydrochloride
nasal spray entered into an initial trial during H2 2013 that was sponsored by the National Institutes of Health (the “Product”);

 

WHEREAS, the
Investor has agreed to invest Three Hundred Thousand Dollars (US$300,000.00) (the “Investment”), which funds
may be used for any Company purpose at the discretion of the Company, which use may include, but is not limited to, the research,
development, marketing, and any other commercialization activities connected to the Product (the “Investment”);
and

.

WHEREAS, the
Company has agreed to assign the Investor the right to receive a certain amount of the financial return produced by the Product;

 

NOW THEREFORE,
with reference to the foregoing facts, the Company and the Investor agree as follows:

 

1.            Investment
and Interest Assignment.

 

1.1           The
Investor shall promptly make the Investment into the Company, which funds may be used for any Company purpose at the discretion
of the Company. In connection with the Investment, the Company hereby agrees to assign the Investor the right to receive, pro rata,
one and a half percent (1.5%) of the net profit generated from the Product in perpetuity from the Effective Date (the “Interest”).
“Net profit” shall be defined as the pre-tax profits generated from the Product after the deduction of all expenses
incurred by and payments made by the Company in connection with the Product, including but not limited to an allocation of Company
overhead based on the proportionate time, expenses and resources devoted by Company to Product-related activities, which allocation
shall be determined in good faith by the Company (the “Net Profit”).

 

2.           
Net Profit Audits, Updates, Distributions and Other Transactions.

 

2.1           The
Company shall provide the Investor with an annual audit of Net Profits (the “Audit”), which Audit shall be completed
after the end of each calendar year.  Notwithstanding the foregoing, this Paragraph 2.1 shall not be applicable until the
Product generates Net Profit.

 

2.2           After
the end of each quarter of the calendar year, the Company shall provide the Investor with a written or electronic update with respect
to the status of the Product. If the Product generates Net Profit, then the Company shall also provide the Investor with a written
or electronic statement of the estimated Net Profit represented by the Interest.

 

3.3           After
the end of each of the first three quarters of the calendar year, the Company shall distribute to the Investor eighty percent (80%)
of such calendar quarter’s Net Profits represented by the Interest, which amount shall be estimated in good faith by the
Company. Upon the completion of the Audit for such calendar year, the Company shall distribute to the Investor the Net Profits
represented by the Interest for the fourth quarter of the calendar year. In the event that the Audit for such calendar year determines
the Net Profits represented by the Interest for the first three quarters of the calendar year (the “Audited NP”)
to be greater than the estimated Net Profits represented by the Interest actually paid to the Investor for the first three calendar
quarters (the “Estimated NP”), then the Company shall distribute to the Investor the difference between the
Audited NP and the Estimated NP. In the event that the Audit for such calendar year determines the Audited NP to be less than the
Estimated NP, then the Company shall deduct the difference between the Estimated NP and the Audited NP from the distribution for
the fourth quarter of such calendar year and, if required, each following distribution until such amount is fully deducted.

 

     

     

    

 

3.4           In
the event that the Product is sold by the Company, then the Investor shall receive one and a half percent (1.5%) of the net proceeds
of such sale, pro rata, and in the form of such net proceeds, after the deduction of all expenses and costs related to such sale.
In the event that the Company is sold, then the Company shall engage an independent financial or accounting firm to determine the
fair value of the Company which is directly attributable to the Product and the Investor shall receive one and a half percent (1.5%)
of such amount after the deduction of all expenses and costs related to such sale. All other material transactions involving the
Product not addressed herein shall be addressed in good faith by the Company and the Investor.

 

3.          
Option to Exchange Interest for Common Stock.

 

3.1           If
the Product is not introduced to the market within twenty-four (24) months after the Effective Date, then the Investor shall have
the option to receive three million seven hundred fifty thousand (3,750,000) shares of the Company’s common stock, par value
$0.001 per share (the “Shares”) in lieu of the Interest (the “Option”).

 

3.2           In
the event that Product is not approved for marketing within twenty-four (24) months after the Effective Date, then the Investor
shall have sixty (60) calendar days to provide written notice to the Company that the Investor intends to exercise the Option.
The Investor shall waive their rights to the Option if the Investor fails to provide sixty (60) calendar days written notice to
the Company of its intent to exercise the Option within such sixty (60) calendar days. If the Investor exercises the Option, then
the Investor shall waive all rights to the Interest and receive fully paid and non-assessable Shares.

 

4.            Representations
and Warranties of the Company.

 

The Company represents
and warrants to the Purchaser that:

 

4.1           The
Company is a public company duly organized, validly existing and in good standing under the laws of Nevada and has all requisite
power and authority to own, lease and operate its properties and assets and to carry on its business as now being conducted and
as proposed to be conducted.

 

4.2           This
Agreement has been duly executed and delivered by the Company and constitutes a valid and legally binding obligation of the Company
enforceable against the Company in accordance with its terms, subject to the effect of bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance and other similar laws relating to or affecting creditors' rights generally, or the availability
of equitable remedies.

  

5.            Representations,
Warranties and Agreements of Investor.

 

The Investor represents
and warrants to, and agrees with, the Company as follows:

 

5.1           Acquisition
for Investment. In the event that the Investor exercises the Option and receives Shares, the Investor is acquiring the Shares
solely for its own account for the purpose of investment and not with a view to or for sale in connection with distribution. In
the event that the Investor exercises the Option and receives Shares, the Investor does not have a present intention to sell the
Shares, nor a present arrangement (whether or not legally binding) or intention to effect any distribution of the Shares to or
through any person or entity. The Investor acknowledges that it is able to bear the financial risks associated with an investment
in the Shares and in the Company and that it has been given full access to such records of the Company and the subsidiaries and
to the officers of the Company and the subsidiaries and received such information as it has deemed necessary or appropriate to
conduct its due diligence investigation and has sufficient knowledge and experience in investing in companies similar to the Company
in terms of the Company’s stage of development so as to be able to evaluate the risks and merits of its investment in the
Company.

 

5.2           Information
on Investor. Investor is, and will be on the Effective Date, an “accredited investor,” as such term is defined
in Regulation D promulgated by the Commission under the 1933 Act, is experienced in investments and business matters, has made
investments of a speculative nature and has purchased shares of United States publicly-owned companies in private placements in
the past and, with its representatives, has such knowledge and experience in financial, tax and other business matters as to enable
the Investor to utilize the information made available by the Company to evaluate the merits and risks of and to make an informed
investment decision with respect to the proposed purchase, which represents a speculative investment. The Investor has the authority
and is duly and legally qualified to purchase and own the Shares. The Investor is able to bear the risk of such investment for
an indefinite period and to afford a complete loss thereof. The information set forth on the signature page hereto regarding the
Investor is accurate.

 

     

     

    

 

5.3           Opportunities
for Additional Information. The Investor acknowledges that the Investor has not received any information from the Company regarding
this Investment. The Investor has the opportunity to ask questions of and receive answers from, or obtain additional information
from, the executive officers of the Company concerning the financial and other affairs of the Company. The Investor has not asked
such questions from the Company and is making its own decision without input and the Investor desires to invest in the Company.

 

5.4           No
General Solicitation. The Investor acknowledges that the Shares were not offered to the Investor by means of any form of general
or public solicitation or general advertising, or publicly disseminated advertisements or sales literature, including (i) any advertisement,
article, notice or other communication published in any newspaper, magazine, or similar media, or broadcast over television or
radio, or (ii) any seminar or meeting to which the Investor was invited by any of the foregoing means of communications.

 

5.5           Rule
144. The Shares may not be offered for sale, sold, assigned or transferred unless such Shares are registered under the Shares
Act or an exemption from registration is available. The Investor acknowledges that the Investor is familiar with Rule 144 of the
rules and regulations of the Commission, as amended, promulgated pursuant to the Shares Act (“Rule 144”), and
that such person has been advised that Rule 144 permits resales only under certain circumstances.

 

5.6           No
Guarantee of Success. The Investor acknowledges that this is a speculative investment involving a high degree of risk and that
there is no guarantee of success or that the Investor will realize any gain from this investment, and the Investor could lose the
total amount of its investment.

 

5.7           Legends.
The Investor hereby agrees with the Company that the Shares will bear the following legend or one that is substantially similar
to the following legend:

 

THE SHARES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SHARES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SHARES LAWS
AND NEITHER SUCH SHARES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED EXCEPT (1) PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SHARES ACT AND APPLICABLE STATE SHARES LAWS OR (2) PURSUANT TO AN AVAILABLE EXEMPTION
FROM THE REGISTRATION REQUIREMENTS OF THE SHARES ACT AND APPLICABLE STATE SHARES LAWS, IN WHICH CASE THE INVESTOR MUST, PRIOR TO
SUCH TRANSFER, FURNISH TO THE COMPANY AN OPINION OF COUNSEL, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY,
THAT SUCH SHARES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED IN THE MANNER CONTEMPLATED PURSUANT TO AN AVAILABLE
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SHARES ACT AND APPLICABLE STATE SHARES LAWS.

 

     

     

    

 

		6.	Miscellaneous.

 

6.1           Notices.  All
notices, requests, demands and other communications (collectively, “Notices”) given pursuant to this Agreement
shall be electronic or in writing, and shall be delivered by email or by personal service, courier, facsimile transmission or by
United States first class, registered or certified mail, postage prepaid, addressed to the party at the address set forth on the
signature page to this Agreement.  Any Notice, other than a Notice sent by registered or certified mail, shall be effective
when received; a Notice sent by registered or certified mail, postage prepaid return receipt requested, shall be effective on the
earlier of when received or the fifth day following deposit in the United States mails.  Any party may from time to time
change its address for further Notices hereunder by giving notice to the other party in the manner prescribed in this Section.
Notwithstanding the foregoing, the Company may send the information set forth in Paragraphs 2.1 and 2.2 via email.

 

6.2           Entire
Agreement.  This Agreement contains the sole and entire agreement and understanding of the parties with respect
to the entire subject matter of this Agreement, and any and all prior discussions, negotiations, commitments and understandings,
whether oral or otherwise, related to the subject matter of this Agreement are hereby merged herein.

 

6.3           Successors.  This
Agreement shall be binding upon and inure to the benefit of the parties to this Agreement and their respective successors, heirs
and personal representatives.

 

6.4           Waiver
and Amendment.  No provision of this Agreement may be waived unless in writing signed by all the parties to
this Agreement, and waiver of any one provision of this Agreement shall not be deemed to be a waiver of any other provision.  This
Agreement may be amended only by a written agreement executed by all of the parties to this Agreement.

 

6.4           Governing
Law.  This Agreement shall be construed in accordance with the laws of the State of Nevada without giving
effect to the principles of conflicts of law thereof.

 

6.5           Captions.  The
various captions of this Agreement are for reference only and shall not be considered or referred to in resolving questions of
interpretation of this Agreement.

 

6.6           Execution.  This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood
that both parties need not sign the same counterpart.  In the event that any signature is delivered by facsimile transmission
or by email delivery of a “pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “pdf”
signature page were an original thereof.

 

[Signature Page Follows]

 

     

     

    

 

IN WITNESS WHEREOF,
the Company and the Investor have duly executed this Agreement as of the day and year first above written.

 

	LIGHTLAKE THERAPEUTICS INC.	/s/ Ernst Welmers
	 	 
	By: 	/s/ Kevin Pollack	 	Name: Ernst Welmers
	 	 
	Its:  CFO	 

 

	Address: 86 Gloucester Place, Ground Floor Suite	Address: 48 Tilman Circle
	 	 
	London, W1U 6HP, UK	Markham, Ontario, Canada
	 	 
	Attn: Dr. Roger Crystal	Attn: Ernst Welmers
	 	 
	Tel.: +44 7812 204 170	Tel: 
	 	 
	Email: roger.crystal@lightlaketherapeutics.com	Email:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]